Midazolam protects B35 neuroblastoma cells through Akt-phosphorylation in reactive oxygen species derived cellular injury by Chong, Won Seog et al.
Korean J Anesthesiol 2012 February 62(2): 166-171 
http://dx.doi.org/10.4097/kjae.2012.62.2.166  Experimental Research Article
Copyright ⓒ the Korean Society of Anesthesiologists, 2012 www.ekja.org
Background: Soman, a potent irreversible acetylcholinesterase (AChE) inhibitor, induces delayed neuronal injury 
by reactive oxygen species (ROS). Midazolam is used in patients with pathologic effects of oxidative stresses such as 
infection, hemodynamic instability and hypoxia. We investigated whether midazolam protects the Central Nervous 
System (CNS) from soman intoxication. The present study was performed to determine whether midazolam protects 
B35 cells from ROS stress for the purpose of exploring an application of midazolam to soman intoxication.
Methods: Glucose oxidase (GOX) induced ROS stress was used in a B35 neuroblastoma cell model of ROS induced 
neuronal injury. To investigate the effect of midazolam on cell viability, LDH assays and fluorescence activated cell 
sorting (FACS) analysis was performed. Western blotting was used for evaluating whether Akt-phosphorylation is 
involved in cell-protective effects of midazolam.
Results: GOX derived ROS injury decreased cell viability about 1.6-2 times compared to control; midazolam 
treatment (5 and 10 μg/ml) dose-dependently increased cell viability during ROS injury. On western blots, Akt-
phosphorylation was induced during pretreatment with midazolam; it was diminished during co-treatment with LY-
294002, an inhibitor of Akt-phosphorylation. FACS analysis confirmed that the cell protective effect of midazolam 
is mediated by an anti-apoptotic effect. GOX-induced apoptosis was inhibited by midazolam and the finding was 
diminished by LY-294002.
Conclusions: Midazolam protects neuronal cells from GOX-induced ROS injury; this effect is mediated by an anti-
apoptotic effect through Akt-phosphorylation. This shows that midazolam may be useful in soman intoxication. 
(Korean J Anesthesiol 2012; 62: 166-171)
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Introduction
Among nerve agents, soman is a major threat partly because 
of the serial toxicologic events following exposure to this 
nerve agent. It is a potent irreversible acetylcholinesterase 
(AChE) inhibitor in the cholinergic nervous system, which can 
produce serial toxic effects [1]. Reactive oxygen species (ROS) 
derived neuronal injury is one of the main mechanisms of 
delayed neuronal injury caused by soman. Intoxication with 
sublethal to lethal doses of soman causes convulsive seizures 
and seizure-related brain damage which are mediated by ROS 
production.
ROS derived from hydrogen peroxide (H2O2), superoxide 
(O2), and peroxynitrite (ONOO) are highly reactive and can lead 
to cell injury [2]. The injured cells exhibit serious responses such 
as inflammation and programmed cell death (e.g. apoptosis). 
Apoptosis is explained by controlled auto-degradation of cells 
and plays important roles in many bio  logical processes inclu-
ding cellular damage, tumorigenesis, and teratogenicity [3]. 
Alter  natively, to protect cells from damage induced by oxidative 
stress, cells have anti-oxidant defense systems and survival-
promoting pathways. The rapid activation or induction of pro-
tective enzymes which decrease oxidative stress by reducing 
ROS increases the capacity of cells to maintain homeostasis 
during oxidative stress; activation of survival-promoting path-
ways allow cells to tolerate and/or to recover from the damage 
[4]. Therefore, modulating these anti-oxidative defense systems 
and survival pathways may influence ROS derived cell injury.
Midazolam, a benzodiazepine derivative, is the most widely 
used anesthetic for sedation. It is also used in critically ill patients 
who usually suffer from the pathologic effects of oxida  tive 
stress such as infection, hemodynamic instability and hypoxia 
[5,6]. Several lines of evidences support an interaction between 
midazolam and ROS. Midazolam interferes with the synthesis 
and release of nitric oxide and tumor necrosis factor-α (TNF-α) 
generated by activated immune cells [7] and inhibits neutrophil 
apoptosis in the perioperative periods. This suggests that 
midazolam may modulate inflammatory cellular injury. 
Through studies of the anti-inflammatory effects of mida-
zolam, we hoped to support the idea that midazolam can 
pro  tect the Central Nervous System (CNS) from soman intoxi-
cation. However, it was necessary to first determine whether 
midazolam activates cell protective mechanisms that are 
involved in soman derived neural cell injury. Therefore, the 
aim of the present study was to explore the hypothesis that 
midazolam protects B35 neuroblastoma cells from ROS stress 
through activation of survival-promoting pathways such as anti-
apoptotic signaling.
Materials and Methods 
Materials
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine 
serum (FBS), penicillin, streptomycin, trypsin/EDTA and 
glutamine were supplied by Gibco-BRL (Rockville, MD, USA). 
ECL western blotting detection reagents and PRO-PREP protein 
extract solution were supplied by iNtRON Biotechnology 
(Houston, TX, USA). Anti-p-Akt antibodies were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-β-actin 
antibody, Glucose oxidase (GOX) and other chemicals were 
purchased from Sigma (St. Louis, MO, USA). 
Cell culture
B35 neuroblastoma cells were purchased from American 
Type Culture Collection (Manassas, VA, USA). For all experi-
ments, cells were grown in DMEM supplemented with 100 U/
ml penicillin, 0.1 mg/ml streptomycin and 10% heat inactivated 
FBS in culture plates. The cells were incubated in a 37
oC 
incubator under 5% CO2 in a humidified atmosphere. After 
reaching confluence, cells were pretreated with various drugs 
depending on the experimental design.
Detection of LDH activity 
Cell viability changes due to GOX and culture conditions 
were determined in terms of LDH released into media of cell 
cultures. Cells in the exponential phase of growth were seeded 
at 1 × 10
4 cells/well in 24-well plates. After different treatments, 
50 ml of standards or 50 ml of culture supernatant (controls and 
treated cells) and 50 ml of substrate mix were transferred into a 
96-well-plate. After incubation for 30 min at room temperature, 
plates were read using a SUNRISE ELISA-plate Reader (Tecan, 
Crailsheim, Germany) at 490 nm. LDH released from cells is 
expressed as a percentage of total cellular LDH. 
Western blot analysis
Whole cell lysates were isolated using PRO-PREP protein 
extract solution. The whole cell lysates were centrifuged at 
100,000 g for 20 min at 4
oC. The protein concentration in each 
lysate was determined by the Bradford assay. To detect Akt-
phosphorylation, 30 micrograms of protein were subjected to 
10% SDS-polyacrylamide gel electrophoresis for 90 min at 120 
V depending on the molecular size of the phospho-Akt protein. 
The separated proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes for 2 h at 20 mA using SD Semi-
dry Transfer Cells (Bio-Rad Laboratories, Hercules, CA, USA). 168 www.ekja.org
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The membranes were stained with Ponceau S solution to 
determine efficiency of transfer and/or protein loading levels. 
Then the PVDF membranes were blocked for 2 h at room 
temperature with 5% nonfat milk in Tris-buffed saline (TBS, pH 
7.0) containing 0.05% Tween 20 (TBS-T). The membranes were 
incubated with an anti-phospho-Akt antibody overnight at 4
oC, 
using a dilution of 1 : 500 in 5% bovine serum albumin (BSA) in 
TBS-T. For the detection of bound antibody, horseradish per-
oxidase conjugated anti-goat or anti-rabbit IgG was used. The 
signals were detected by ECL using a western blotting luminol 
reagent system (iNtRON Biotechnology, Houston, TX, USA) and 
autoradiography.
FACS analysis 
A total of 1 × 10
7 cells were seeded in 100 mm culture dishes, 
incubated at 37
oC, and harvested at the indicated times after 
mitosis. Cells were stained with propidium iodide (PI) using 
a previously described method [8]. The harvested cells were 
trypsinized, washed twice in PBS, and fixed in 70% ethanol 
on ice for a minimum of 2 h. Cells were washed 2 additional 
times with PBS and stained for 30 min at 37
oC in 50 μg/ml PI 
solution containing 200 μg/ml RNase A and 0.1% Triton X-100. 
After incubation of samples in the dark for 30 minutes, cell 
cycle profiles were determined using a Beckton-Dickinson flow 
cytometer (Becton Dickenson Biosciences, San Jose, CA, USA) 
with CellQuest
Ⓡ Software. 
Statistical analysis 
Values are expressed as means ± SD. Differences between 
data sets were assessed by one-way analysis of variance 
(ANOVA) followed by the Newman-Keuls test. P < 0.05 was 
regarded as statistically significant.
Results
Akt phosphorylation is responsible for the protective 
effect of midazolam against ROS damage
The effects of midazolam on cell viability during ROS injury 
were analyzed by LDH assay. As expected, 10 h of incubation 
with 20 mU/ml of GOX significantly decreased cell viability. Fig. 
1A shows that GOX derived ROS injury decreased cell viability 
about 1.6-2 times compared to the control. However, treatment 
with midazolam (5 and 10 μg/ml) concentration-dependently 
reduced the decreased cell viability due to ROS injury, and this 
difference was statistically significant. To determine the effect 
of an Akt-phosphorylation inhibitor on cell viability, 5 μM 
concentrations of LY294002 were used to treat cells for 1 h prior 
to treatment with midazolam. As shown in Fig. 1B, LY294002 
inhibited the protective effect of midazolam. For example, 
pretreatment with 5 μM LY294002 significantly decreased cell 
viability that had been induced by midazolam. 
Fig. 1. The Cytoprotective effect of midazolam on GOX (Glucose Oxidase) derived ROS injury in B35 rat neuroblastoma cells. (A) The 
cytoprotective effect of midazolam against ROS derived cell death was measured by LDH production. Cells were pretreated with different 
concentrations of midazolam for 8 h, and then exposed to 20 mU/ml of GOX for 10 h. (B) The protective effect of midazolam against ROS injury 
was diminished by treatment with LY294002. Pretreatment of LY294002 (5 μM) was done during 1 h before incubation of cells with 5 μg/ml of 
midazolam for 8 h. Thereafter, cells were exposed to 20 mU/ml of GOX for 10 h. Data represent means ± SD of three independent experiments (*P < 
0.01, compared with the control, 
†P < 0.01, compared with GOX derived ROS injury, 
‡P < 0.01, compared with midazolam). 169 www.ekja.org
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Dose-dependent induction of Akt-phosphorylation by 
midazolam is mediated through PI3 kinase activation
We next asked whether midazolam can protect B35 cells 
from oxidative stress induced injury by regulating Akt-phos-
phorylation. Akt phosphorylation plays important roles in 
general cellular defense systems against oxidative stress in 
mammalian cells. As shown in Fig. 2, western blot analysis 
indicated that midazolam-induced cytoprotective effects in ROS 
injury may be mediated by induction of Akt-phosphorylation 
Fig. 3. Akt-phosphorylation mediates the cytoprotective effect of midazolam against GOX-induced apoptosis. A fixed concentration of GOX 
(20 mU/ml) was used along with midazolam (5 μg/ml) with/without LY-294002 (5 μM). After a 10 h incubation with only GOX, FACS analysis 
was performed. (A) Under no pretreatment, apoptosis was not significant. (B) Apoptosis was induced by GOX. (C) When cells were pretreated 
with midazolam for 8 hrs before GOX treatment, apoptosis was diminished. (D) The anti-apoptotic effect of midazolam was abolished by co-
treatment with LY-294002. 
Fig. 2. PI3K-dependent Akt-phosphorylation mediated by midazolam in B35 neuroblastoma cells. (A) The upper panel shows that midazolam 
increases levels of phosphorylated-Akt protein in a concentration-dependent manner. After treatment with the indicated concentrations of 
midazolam for 8 h, western blotting was performed. (B) The upper panel shows that midazolam induced phospho-Akt protein expression was 
diminished by LY-294002, an inhibitor of PI3 kinase. The indicated concentrations of the PI3 kinase inhibitor, LY-294002, were added 30 min 
prior to midazolam, and western blotting was performed after an 8 h incubation.170 www.ekja.org
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through PI3 kinase activation. The effect of midazolam on 
Akt-phosphorylation was dose dependent, but the induction 
was abolished by pretreatment with LY294002, a PI3 kinase 
inhibitor. 
Midazolam inhibits GOX-induced apoptosis through 
Akt phosphorylation
It is generally known that ROS induces apoptosis in many 
mammalian cells [9] and GOX is frequently used as a chronic 
ROS producing agent [10]. Therefore, we investigated whether 
midazolam protects cells from GOX-induced apoptosis. Fig. 3 
shows that GOX-induced apoptosis was diminished by mida-
zolam pretreatment. The effect is mediated through Akt-
phosphorylation because the diminished apoptosis due to 
addition of midazolam became obvious again as the con-
centration of LY294002, an inhibitor of PI3 kinase, increased. 
FACS analysis (Fig. 3) showed that about 61 % of cells 
underwent apoptosis after GOX (20 U/ml), but pretreatment 
with midazolam significantly reduced the fraction of dead cells 
to 21%. Co-treatment with LY294002 significantly reduced the 
anti-apoptotic effect of midazolam. 
Discussion
The major finding of this study is that the midazolam in-
creases Akt phosphorylation through PI3 kinase activation 
and significantly decreases GOX-induced apoptotic cell 
death in B35 cells. This conclusion is based on the findings 
that: (1) midazolam concentration-dependently induces 
phosphorylation of Akt in B35 cells; (2) LY-294002, a PI3 
kinase inhibitor, significantly inhibits the protective effect of 
midazolam against ROS injury. 
For application of the results of the present study to an in vivo 
study, pharmacological concentrations have to be considered. 
The concentrations used (1, 5 and 10 μg/ml) in the present 
study were chosen based on the report of Hudson [11]. In the 
report, midazolam was given to patients with abdominal aortic 
surgery at 0.25 mg/kg and the maximum plasma concentration 
(Cmax) ranged from 200 to 3,000 ng/ml. Several studies reported 
that midazolam has antioxidant effects, and these effects could 
make midazolam effective against pathologic states mediated 
by oxidative stresses [5,6]. Interestingly, the findings in this 
study indicate that the beneficial effects of midazolam on ROS-
induced pathologic states may also be regulated by induction of 
pro  tective mechanisms such as Akt-phosphorylation. 
However, the finding in the present study does not coincide 
with the study of Stevens et al. [12]. They reported pro-apoptotic 
effects of midazolam in human Jurkat T-lymphoma cells and 
human neuroblastoma cells via regulation of mitochondrial 
pathways at midazolam concentrations ranging from 100 to 
400 μM (over 24 hr). These finding are not consistent with 
results of the present study, but this could be because several 
factors in the two studies were different. We exposed cells for 
only 8 hrs. The concentrations of midazolam and the duration 
of the pre-incubation step were different. In the present 
study, we used midazolam concentrations of 1, 5 and 10 μg/
ml which correspond, respectively, to 0.31 μM (1 μg/ml), 1.53 
μM (5 μg/ml) and 3.1 μM (10 μg/ml). Thus, midazolam may 
induce apoptosis at higher concentrations that are more toxic 
concentration but this has to be evaluated further to confirm 
that midazolam has dual effects on apoptosis depending on its 
concentration.
Generally, it is well-recognized that Akt-phosphorylation 
plays a major role in cell proliferation and survival in many 
cell types and is classically activated by phosphoinositide-
dependent kinases following recruitment to the plasma 
membrane by products of the type I phosphoinositide 3-kinase 
[13]. However, the fact that midazolam may serve a critical role 
in a cell’s protective mechanism during oxidative stress through 
Akt phosphorylation is a novel finding. 
Originally, this exploratory study was done to determine 
whether midazolam can protect cells from soman induced 
neural injury. Because ROS are involved in the neurotoxicity 
or neuronal injury during soman intoxication [14,15], we 
deliberately used 20 mU/ml GOX to simulate a pathologic state 
where the generation of sustained and continual release of 
H2O2 can give rise to oxidative stress [16]. Therefore, the anti-
apoptotic effect of midazolam in GOX-induced ROS injury 
supports the idea that midazolam has a beneficial effect in 
soman intoxication. 
In summary, we showed that midazolam, a benzodiazepine, 
leads to phosphorylation of Akt in neuronal cells through 
activation of the PI3 kinase pathway. This induction of Akt-
phosphorylation is responsible for the protection of B35 cells 
from GOX-induced oxidative stress. Thus, we conclude that 
midazolam is important in the management of soman-induced 
neuronal injury. 
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